European Journal of Medicinal Chemistry p. 22 - 31 (2019)
Update date:2022-08-02
Topics:
Ndikuryayo, Ferdinand
Kang, Wei-Ming
Wu, Feng-Xu
Yang, Wen-Chao
Yang, Guang-Fu
Involved in the tyrosine degradation pathway, 4-hydroxyphenylpyruvate dioxygenase (HPPD) is an important target for treating type I tyrosinemia. To discover novel HPPD inhibitors, we proposed a hydrophobicity-oriented drug design (HODD) strategy based on the interactions between HPPD and the commercial drug NTBC. Most of the new compounds showed improved activity, compound d23 being the most active candidate (IC50 = 0.047 μM) with about 2-fold more potent than NTBC (IC50 = 0.085 μM). Therefore, compound d23 is a potential drug candidate to treat type I tyrosinemia.
View MoreContact:+44 (0)208 191 7890
Address:Unit11, Ark Business Centre, Gorden Road, Loughborough, United Kingdom
Shanghai Biobond Pharmaceutical Co.,Ltd
website:http://www.sh-biobond.com/EnglishIndex.aspx
Contact:021-68719686 /18939786273/ 18917373795
Address:Shanghai Zhangjiang
RongCheng Tianyu Technology Co.,Ltd.
Contact:86-631-7519595
Address:220Ping Donghai Road RongChengCity,ShangDong Province China
Weifang Dongxing Chitosan Factory
website:http://dxchitosan.lookchem.com/
Contact:13475651157
Address:Weifang city ,shandong province
Tianjin Boron PharmaTech Co.,Ltd.(expird)
Contact:86-022-59845187
Address:B9-401, Tianda Science Park,No.80,4th Avenue,TEDA,Tianjin, China
Doi:10.1016/j.tet.2011.05.109
(2011)Doi:10.1007/BF00472493
(1990)Doi:10.1021/jacs.8b04581
(2018)Doi:10.1080/10426507.2010.511512
(2011)Doi:10.1021/ol201930e
(2011)Doi:10.2174/157017811796064485
(2011)